How Can We Help You?


Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Gastric Cancer

Select Clinical Trial

Protocol Number: Amgen 20210096 (FORTITUDE-101)

Protocol Title: A randomized, double-blind, placebo-controlled phase 3 study of Bemarituzumab plus chemotherapy versus placebo plus chemotherapy in subjects with previously untreated advanced gastric or gastroesophageal junction cancer with FGFR2b Overexpression

Eligibility: Men and women age 18 and older with unresectable, locally advanced, or metastatic histologically documented gastric or GEJ adenocarcinoma.

Contact Information: (910) 715-2200


Clara McLean House
Make a Donation
News & Events